The Role of Residual Renal Function in Diabetic Peritoneal Dialysis Patients
Journal of Clinical Nephrology and Therapeutics publishes the manuscripts that are directly or indirectly based on variegated aspects of clinical nephrology, diabetic nephropathy, pediatric nephrology, renal physiology, renal histopathology, immunobiology, intensive care nephrology, and ischemic nephropathy.
Articles that are submitted to our journal will undergo a double-blind peer review process to maintain quality and the standards set for academic journals. The review process will do by our external reviewers which are double-blind. The comments will upload directly to the editorial tracking system. Later the editor will check the comments whether it is acceptable or not. The overall process will take around 21 days under with the editor. After acceptance by the editor, it will be published on the Press page. Authors can submit their manuscripts to the online submission portal.
Peritoneal dialysis (PD) is a treatment method used in home renal replacement therapy. Recently, there has been a greater focus on residual renal function (RRF) in PD patients. RRF in PD patients is clinically significant, as it contributes to the survival of the treatment, as well as patient mortality rates. Not only does decrease RRF cause poor management of water removal, but it also increases the risk of mortality as well as PD withdrawal due to overhydration. Diabetic patients are at higher risk of mortality/comorbidities and loss of RRF than patients with other diseases. Loss of RRF is the main cause of overhydration, poor quality of life (QOL), withdrawal of PD, and high mortality rate in dialysis patients; therefore, it is clinically important to maintain RRF. Control of blood pressure, inhibition of the renin-angiotensin system, decreased proteinuria, dietary intervention, avoidance of nephrotoxins, and glucose control should be considered for maintaining RRF in dialysis patients. Additionally, sarcopenia and frailty are issues of significant importance, especially in patients with end-stage renal disease (ESRD). As metabolic acidosis can be a complication of ESRD, anemia, uremia and appetite loss are side effects; loss of appetite and inflammation are also associated with mortality. To ensure good QOL, PD survival, and low mortality risk, it is imperative to maintain RRF. Aside from the use of icodextrin or large amounts of diuretics, tolvaptan – often used at the initiation of PD in patients with overhydration – may also be beneficial in maintaining RRF. RRF that is positively maintained aids in enhancing the appetite and improving malnutrition and inflammation, both of which contribute to loss of RRF. Moreover, the enhanced appetite may improve QOL and prevent the possibility of sarcopenia and frailty in PD patients. In hemodialysis patients, tolvaptan also may be useful in the preservation of RRF and decreased mortality rate, as well as improved QOL.
Journal of Clinical Nephrology and Therapeutics